Source · Select Committees · Public Accounts Committee
Recommendation 30
30
Accepted in Part
Veterinary Medicines Directorate published framework to address UK veterinary vaccine availability issues
Conclusion
In September 2025, the Veterinary Medicines Directorate published a Statement of Intent on UK Veterinary Vaccine Availability. This sets out a framework for future cross-sector action to address the mismatch between supply and demand for existing veterinary vaccines and facilitate the pipeline of innovative products to address existing and emerging therapeutic gaps.45 The Pirbright Institute highlighted the important work of The Centre for Veterinary Vaccine Innovation and Manufacturing. The Centre will support the development and deployment of vaccine technologies to combat neglected and emerging diseases of livestock, including zoonotic diseases that represent a threat to public health.46
Government Response Summary
VMD's Statement of Intent outlines a strategic framework for cross-sector action. A five-year multi-stakeholder Action Plan will be published late 2026, and mitigations for urgent availability issues are being identified and actioned. Defra worked with manufacturers to expedite emergency use of a Bluetongue 3 vaccine and is supporting the avian influenza vaccine taskforce.
Government Response
Accepted in Part
HM Government
Accepted in Part
The government agrees with the Committee’s recommendation. Target implementation date: November 2026 8.2 The Veterinary Medicines Directorate’s (VMD) Statement of Intent for UK veterinary vaccine availability outlines a strategic framework for cross-sector action. VMD is continuing cross-sector engagement to identify ways to improve supply and enable future innovation (involving government, pharmaceutical manufacturers, vet groups and broader animal health community). A five-year multi-stakeholder Action Plan will be published late 2026. Defra will work with VMD as the plan is developed. In parallel, mitigations for urgent availability issues are being identified and actioned. 8.3 Action has already been taken to secure animal vaccine supply to the UK. For example, in 2024, Defra worked with manufacturers, industry and the VMD to expedite emergency use of a Bluetongue 3 vaccine and subsequently to manage supply challenges. 8.4 Defra supported the joint industry-government avian influenza vaccine taskforce (the Taskforce) to look at the emerging use of HPAI vaccines. A report published by the Taskforce on 24 July 2025 provisionally recommends a future species-specific vaccination strategy, and a trial in turkeys. The Taskforce has committed to publish a subsequent report in Summer 2026. 8.5 In relation to vaccine development work for Bovine TB, an application for approval of the Cattle BCG vaccine was made in September 2025 and is being assessed by the Veterinary Medicines Directorate according to published timelines. APHA continues work towards generation of data for the bovine TB cattle vaccine skin test which involves a commercial contract and tender exercise.